Lapatinib – Kapesitabin Tedavisi Sırasında Kranial Radyoterapi İle İndüklenen Cilt Toksisitesi: Bir Olgu Sunumu

Abstract

Epidermal büyüme faktörü reseptörü (EGFR), akciğer kanseri, meme kanseri, kolorektal kanser dahil olmak üzere birçok farklı kanser türünde aşırı eksprese edilmektedir. Meme kanserinde hastaların %15-20’sinde insan büyüme faktör reseptörü -2 (HER-2) aşırı ekspresyonu olup hastalık progresyon riskinde artış ve genel sağ kalım süresinde azalma ile ilişkilidir. Lapatinib, HER-2 ve EGFR’nin ikisini de inhibe eden ilk tirozin kinaz inhibitörüdür. Anti - EGFR ajanlar; cilt, tırnak, saç ve göz toksisiteleri ile ilişkilendirilmektedir. Dermatolojik toksititeler tedavinin kesilmesine neden olabilmekte ve hastanın yaşam kalitesini etkileyebilmektedir. Bu yazıda metastatik meme kanseri nedeniyle lapatinib ve kapesitabin kullanmaktayken tüm beyin radyoterapisi sonrası, sadece yüz bölgesine lokalize fotosensitivite reaksiyonu gözlenen bir olgu sunulmaktadır.

Keywords

• lapatinib,meme kanseri,cilt toksititesi

References

1. 1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. NatRevCancer 2005;5:341-54.10.1038/nrc1609.
2. 2. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426-47.
3. 3. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitör blocks EGF activation of EGFR/erbB2 and down stream Erk1/2 and AKT pathways. Oncogene 21:6255–6263. doi: 10.1038/sj.onc.1205794
4. 4. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabin eversus capecitabine lone in women with advanced breast cancer that has progressed on trastuzumab: update defficacy and biomarker analyses. Breast Cancer ResTreat. 2008;112:33–43. doi: 10.1007/s10549-007-9885-0
5. 5. Zhou H, Kim Y-S, Peletier A, McCall W, Earp HS, Sartor CI (2004) Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-over expressing breast cancer cellline proliferation, radiosensitization, and resistance. Int J RadiatOncolBiolPhys58:344–352. doi: 10.1016/j.ijrobp.2003.09.046.
6. 6. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007;43(5): 845–51.) (Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23(22):5235–46.) (Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006;155:852–854.
7. 7. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Available from: (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ docs/ctcaev3.pdf). Accessed March 16, 2009.
8. 8. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657.

9. 9. Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132:236.
10. 10. Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci. 1997;110:113–21.
11. 11. El-Abaseri TB, Putta S, Hansen LA. Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 2006;27:225–231.
12. 12. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007;32:71-74.
13. 13. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27(33):5538–46.
14. 14. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26(34):5544–52.
15. 15. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006;355(26):2733–43.